Valaris (VAL)
(Delayed Data from NYSE)
$72.91 USD
+0.48 (0.66%)
Updated Jul 10, 2024 04:00 PM ET
After-Market: $72.89 -0.02 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
VAL 72.91 +0.48(0.66%)
Will VAL be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for VAL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VAL
Precision Drilling (PDS) Q1 Earnings and Revenues Miss Estimates
Valaris (VAL) Receives Rig's Suspension Notice From Aramco
VAL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Equinor (EQNR) Begins Production at Brazil's Mendubim Plant
ExxonMobil (XOM), Shell Partner With Singapore for CCS Project
Textron and RCI Hospitality have been highlighted as Zacks Bull and Bear of the Day
Other News for VAL
Shipping Trends: J Mintzmyer And Edward Finley-Richardson On Marine Money 2024
ValiRx AGM: Majority Resolutions Passed
ValiRx Plc Announces Board Chairman Resignation
IN BRIEF: ValiRx shares up as subsidiary inks contract with US firm
ValiRx Subsidiary Inaphaea Secures US Biotech Contract